摘要
目的探讨氯沙坦和环磷腺苷葡胺联合治疗肺心病患者的效果。方法回顾性分析2016年2月至2018年3月周口市人民医院116例肺心病患者的临床资料,根据用药方案的不同分为对照组(氯沙坦单药治疗,58例)与观察组(氯沙坦与环磷腺苷葡胺联合治疗,58例)。比较两组治疗前后免疫功能[补体C3、免疫球蛋白A(IgA)、IgG]与心肺功能指标[右心室射血分数(RVEF)、右心室舒张末期容积(RVEDV)、右心室收缩末期容积(RVESV)、第1秒用力呼气容积(FEV1)、分钟静息通气量(VE)、肺动脉收缩压(PAP)]变化情况。结果治疗1个疗程后,两组IgA、IgG水平比较,差异未见统计学意义(P>0.05)。观察组补体C3水平[(1.35±0.12)g/L]、RVEF[(55.79±6.21)%]、FEV1[(1.83±0.26)L]、VE[(4.32±0.41)L]均高于对照组[(1.16±0.09)g/L、(51.09±5.62)%、(1.48±0.35)L、(3.89±0.52)L],RVESV[(36.67±1.57)ml]、RVEDV[(45.23±1.86)ml]与PAP[(45.63±5.22)mmHg]均低于对照组[(39.36±2.08)ml、(47.88±2.61)ml、(50.75±6.23)mmHg],差异有统计学意义(P<0.05)。结论氯沙坦和环磷腺苷葡胺联合治疗肺心病患者,可有效改善免疫功能,有利于调节心肺功能。
Objective To investigate the therapeutic effect of combined treatment of losartan and cyclophosphamide glucosamine on patients with pulmonary heart disease. Methods The clinical data of 116 patients with pulmonary heart disease from February 2016 to March 2018 in Zhoukou People’s Hospital were retrospectively analyzed. According to the different medication regimens, the patients were divided into control group(losartan alone, 58 cases) and observation group(losartan combined with meglumine cyclophosphate, 58 cases). Immune function [complement C3, immunoglobulin A(IgA), IgG] and cardiopulmonary function indicators [right ventricular ejection fraction(RVEF), right ventricular end diastolic volume(RVEDV), right ventricular end systolic volume(RVESV), forced expiratory volume(FEV1), minute rest ventilation volume(VE), pulmonary artery systolic pressure(PAP) ]were compared before and after treatment between the two groups. Results After one course of treatment, the IgA and IgG levels of the two groups were compared, and the differences were not significant(P>0.05). The levels of complement C3[(1.35±0.12)g/L], RVEF[(55.79±6.21)%], FEV1[(1.83±0.26)L] and VE[(4.32±0.41)L] in the observation group was higher than those in the control group[(1.16±0.09)g/L,(51.09±5.62)%,(1.48±0.35)L,(3.89±0.52)L], while the levels of RVESV[(36.67±1.57)ml], RVEDV[(45.23±1.86)ml] and PAP[(45.63±5.22)mmHg] were lower than those in the control group[(39.36±2.08)ml,(47.88±2.61)ml,(50.75±6.23)mmHg], with significant differences(P<0.05). Conclusions Losartan combined with meglumine adenosine cyclophosphate in the treatment of patients with pulmonary heart disease can effectively improve the immune function, which is conducive to the regulation of cardiopulmonary function.
作者
徐春芝
Xu Chunzhi(Department of Cardiovascular Internal Medicine,Zhoukou People's Hospital,Zhoukou 466001,China)
出处
《临床医学》
CAS
2019年第11期85-87,共3页
Clinical Medicine
关键词
肺心病
氯沙坦
环磷腺苷葡胺
免疫功能
心肺功能
Pulmonary heart disease
Losartan
Cyclophosphamide glucosamine
Immune function
Cardiopulmonary function
